Healthcare & Life Sciences

Collection Device with Valve for Liquid Specimen Patent Granted

The USPTO granted Patent US12605149B2 to Zhongshan Ophthalmic Center of Sun Yat-Sen University on April 21, 2026, covering a collection device with a valve for liquid specimens. The device comprises a reservoir with a sealed cavity under negative pressure, a delivery tube with a valve between inlet and outlet, and a piercing component for tissue access. The patent contains 19 claims and was filed on May 30, 2018 under Application No. 16980417.

US12605518B2 Gas Passage for PAP Device with Noise Reduction

USPTO granted Patent US12605518B2 to WALLENBERG UNION LLC on April 21, 2026, covering a gas passage for use in a PAP (positive airway pressure) device with integrated noise reduction components. The patent claims 25 items and was filed on July 19, 2024, under Application No. 18778376. The invention includes a passage casing with air intake and outlet, a chamber for gas flow and accumulation, a blower, and noise reduction elements including a ventilation component, intake pipe, and flexible component.

Positive Pressure Breathing Device Patent Granted April 21 2026

USPTO granted Patent US12605521B2 to inventor Hsin-Yung Lin on April 21, 2026 for a breathing equipment device that provides positive pressure gas. The device combines a hydrogen generating device (using water electrolysis), a pressurizing device, a mixing device, an atomizing device, and an output device, all coupled to a gas channel. The patent contains 18 claims and covers methods for generating and delivering hydrogen gas mixed with positive pressure gas for therapeutic applications.

CPAP Humidifying Tank Patent, Murata Manufacturing, Granted

USPTO granted patent US12605522B2 to Murata Manufacturing Co., Ltd. on April 21, 2026, covering a CPAP apparatus humidifying tank design with improved flow-dividing and shielding sections. The patent application (18302850) was filed April 19, 2023, and contains 8 claims under CPC classifications A61M 16/00 through A61M 2205/123.

Boston Scientific Scimed Treatment Agent Delivery System Patent Granted

USPTO granted Patent US12605151B2 to Boston Scientific Scimed, Inc. on April 21, 2026, covering a treatment agent delivery system with 20 claims. The patent protects a medical device including a handle with an actuator, a shaft, an actuation member, a cartridge containing a treatment agent, and a plunger, where movement of the actuator controls delivery of the treatment agent from the cartridge. Inventors are Paul Smith, Travis Henchie, and Peter L. Dayton. The patent application was filed on April 12, 2023, under Application No. 18299161.

Becton Dickinson IV Catheter with Side Port for Blood Draw

The USPTO granted Patent US12605096B2 to Becton, Dickinson and Company on April 21, 2026, covering an integrated intravenous catheter device with a side port enabling simultaneous blood draw and fluid injection. The patent (application 17143979, filed January 7, 2021) contains 17 claims and CPC classifications spanning A61B 5/15, A61M 20/39, and A61M 25/00. Named inventor is Jithendra Kumar Sathyanarayana Naidu. The invention facilitates blood sample collection at the time of catheter insertion by providing separate fluid pathways for drawing blood and injecting fluids via an extension set.

Microneedle Electrical Interface Patent Granted to Biolinq

The USPTO granted Patent US12605100B2 to Biolinq Incorporated on April 21, 2026, covering methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure. The patent describes a microneedle-based electrochemical biosensor structure comprising a substrate, microneedle biosensor, primary and secondary electrically conductive elements, and an electrically insulative annular barrier. The patent application (No. 19258472) was filed July 2, 2025, and contains 26 claims.

Belhaven BioPharma Intranasal Epinephrine Delivery Device Patent

Belhaven BioPharma Inc. received US Patent 12605517B1 on April 21, 2026, titled 'Compositions, devices, and methods for intranasal delivery of dry powder epinephrine.' The patent contains 15 claims and names Scott Lyman and Brian Taubenheim as inventors. The patented compositions include epinephrine with a stabilizing agent (citric acid or salt) and carrier for intranasal dry powder delivery. The patent is assigned under CPC classifications A61M 15/08, A61M 11/003, A61K 9/0043, and A61K 31/137. Belhaven BioPharma now holds enforceable intellectual property rights to this intranasal epinephrine formulation in the United States. Competitors developing similar intranasal epinephrine delivery systems for anaphylaxis or respiratory conditions should conduct Freedom to Operate analyses to assess potential infringement exposure.

NeuroLight Neuroenhancement Patent US12605104B2, Granted Apr 21

The USPTO granted Patent US12605104B2 to NeuroLight, Inc. on April 21, 2026, covering a method of facilitating skill learning or improving task performance through brainwave pattern analysis and targeted stimulation. The patent includes 23 claims under CPC classification A61M 21/00 and names Alexander I. Poltorak as the sole inventor. The application was filed on August 14, 2023, under application number 18233835.

Drägerwerk Patent for Breathing Activity Determination Granted

The USPTO granted US Patent 12605519B2 to Drägerwerk AG & Co. KGaA on April 21, 2026, covering a process and signal processing unit for determining pneumatic indicators for a patient's breathing activity. The patent, with 19 claims, describes technology that generates respiratory signals from measured values and determines two pneumatic indicators describing the activity of different regions of the respiratory system.

Visual Pressure Regulating Catheter Patent - Qingdao Biotech Medical

USPTO granted Patent US12605161B2 to QINGDAO BIOTECH MEDICAL CO., LTD on April 21, 2026, covering a visual pressure regulating catheter with integrated hydraulic dilation balloon, pressure regulating handle, endoscope pressure regulating cavity, and dilation liquid perfusion cavity. The invention enables direct endoscopic observation through the catheter into the dilation balloon. The patent contains 13 claims and lists CPC classifications spanning A61B, A61M, and related medical device categories.

US12605094B2 - Closed Arterial Blood Collection Apparatus

USPTO granted Patent US12605094B2 to MUNE CO., LTD. on April 21, 2026 for a closed type arterial blood collection apparatus comprising a saline bag with first and second ports, an A line, first and second three-way valves, a blood collection unit, and a fluid conveying means. The patent application was filed December 28, 2022 under application number 18270088, with 5 claims and multiple CPC classifications including A61M 5/44 and A61B 5/15.

COSALFA 52 Meets in Guyana, Advancing Foot-and-Mouth Disease Eradication

The 52nd Ordinary Meeting of COSALFA opened in Georgetown, Guyana on April 22, 2026, convening delegates from member countries, international organizations, and private sector representatives to advance the Region's progress toward eradicating foot-and-mouth disease. PAHO Director Dr. Jarbas Barbosa stated via video that the Americas is entering the final stage of eradication, with the inclusion of Venezuela on the WOAH-recognized list as a key remaining objective. Key agenda items included the new 2026-2030 Action Plan of PHEFA, Caribbean emergency preparedness, and the first year of operation of the Regional Antigen Bank (BANVACO).

Bahamas WHO-Certified for Eliminating Mother-to-Child HIV Transmission

The World Health Organization and Pan American Health Organization certified The Bahamas on April 22, 2026 as having eliminated mother-to-child transmission of HIV, making it the latest Caribbean nation to achieve this milestone. The Bahamas joins 12 countries and territories in the Region of the Americas certified for EMTCT, having met WHO's thresholds of less than 2% mother-to-child transmission rate, fewer than 5 new pediatric HIV infections per 1,000 live births, and 95% or higher coverage for antenatal care, HIV testing, and treatment. The achievement reflects sustained political commitment, universal antenatal care regardless of nationality or legal status, integrated laboratory networks, and multi-month dispensing of antiretroviral medicines.

PROTECT Project Advances Early Warning Systems Along South American Bioceanic Corridors

PAHO reported on April 22, 2026 that six South American countries — Argentina, Bolivia, Brazil, Chile, Paraguay, and Peru — reviewed progress on coordinated early warning systems for public health threats along biooceanic corridors. The work, under the PROTECT project (Pandemic Response Optimization Through Engaged Communities and Territories), builds on foundations laid in October 2025 in Asunción, Paraguay, and targets governance, systems interoperability, epidemiological surveillance, laboratory capacities, and workforce development through the end of 2026. The initiative is funded by the Pandemic Fund and implemented jointly by PAHO, the World Bank, and PANAFTOSA/SPV.

Diaphragmatic Breathing vs Incentive Spirometry for GERD - NCT07544433

Clinical trial NCT07544433 registered on ClinicalTrials.gov evaluates two non-invasive respiratory interventions—diaphragmatic breathing exercise (DBE) and volume-oriented incentive spirometry (VIS)—against standard care in patients with gastroesophageal reflux disease (GERD). The 6-week randomized controlled trial will measure outcomes including GERD symptom scores (GERDQ), esophageal acid exposure time, lower esophageal sphincter pressure, and health-related quality of life (GERD-HRQL). Three groups of participants will undergo baseline and post-intervention assessments with daily symptom and adherence diaries.

Prospective Study of Minimally Invasive Hernia Repair, 5-Year Follow-up

NIH's ClinicalTrials.gov registered an observational study (NCT07544238) on April 22, 2026, examining clinical outcomes of minimally invasive (laparoscopic and robotic) hernia repair over a 5-year follow-up period. Adult patients scheduled for elective abdominal wall hernia repair (not inguinal) will be tracked at 2-3 months, 1 year, 3 years, and 5 years post-surgery, with CT imaging at 1 year and as needed for complication suspicion. The study will analyze recurrence rates, intra- and postoperative complications, quality of life, aesthetic outcomes, and pain using standard treatment protocols.

Phase 3 Megestrol Acetate Trial for T-DXd-Related Fatigue in Advanced Breast Cancer

ClinicalTrials.gov registered a new Phase 3 interventional study (NCT07543536) on April 22, 2026, evaluating whether Megestrol Acetate administered at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can prevent or alleviate T-DXd-related fatigue in patients with advanced or metastatic HER2+, HER2-low, or HER2-ultralow breast cancer. The trial will compare Megestrol Acetate plus T-DXd against placebo plus T-DXd. The study is sponsored by an unnamed party and is classified as Phase 3.

Serum Electrolytes and Contrast-Induced Nephropathy in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment

A new observational cohort study (NCT07546448) has been registered on ClinicalTrials.gov, examining the relationship between serum electrolyte levels and contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT). The retrospective study will analyze patients treated between 2018 and 2026, classifying participants based on the presence or absence of CI-AKI per serum creatinine changes, with secondary objectives including 90-day mortality and dialysis dependency evaluation.

Nursing Intervention Based on Stress Adaptation Theory for Patients Undergoing Diabetic Retinal Laser Surgery

A randomized controlled study registered on ClinicalTrials.gov under NCT07544381 evaluates whether a nursing intervention based on stress adaptation theory improves pain trajectory and procedural tolerance in patients undergoing ambulatory retinal laser photocoagulation for diabetic retinal disease. Patients were randomized to receive routine peri-procedural care or routine care plus a structured nursing intervention including a brief treatment pause, guided slow breathing, anticipatory communication, real-time reassurance, and post-procedure observation. Outcomes measured include pain intensity, physiologic responses, procedural cooperation, and adverse events.

MBP vs No MBP in Laparoscopic Right Hemicolectomy

A randomized controlled trial (NCT07546565) registered at University Medical Center Ho Chi Minh City will compare mechanical bowel preparation (MBP) versus no MBP in patients undergoing laparoscopic right hemicolectomy with intracorporeal anastomosis for colon cancer. The trial will enroll eligible patients randomly assigned to either group and measure surgical site infection rates within 30 days as the primary outcome, alongside secondary outcomes including anastomotic leakage, postoperative ileus, operative time, and length of hospital stay. Findings aim to clarify whether MBP reduces postoperative infections in this specific surgical context.

Teen Vulnerability to Irritability: Brain and Estrogen Changes (NCT07544966)

NIH registered a Phase 4 clinical trial (NCT07544966) titled "Teen Vulnerability to Irritability: Brain and Estrogen Changes," enrolling 50 female adolescents ages 12-16 at risk of suicide. The randomized, placebo-controlled, cross-over study will test the impact of estradiol (E2) and progesterone (P4) stabilization via continuous combined oral contraceptive (Kurvelo) versus placebo on brain networks associated with irritability over two 8-week treatment arms. Each participant undergoes daily hormone sampling, daily symptom ratings, and neuroimaging sessions across conditions.

ADHELASKIN for Systemic Sclerosis Skin Assessment (NCT07543679)

A clinical trial (NCT07543679) evaluating ADHELASKIN technology by Tactinnov and École Centrale de Lyon for objective assessment of skin damage in patients with systemic sclerosis has been registered on ClinicalTrials.gov. The trial addresses limitations of the modified Rodnan skin score (mRSS), including inter- and intra-observer variability and limited sensitivity to subtle changes. ADHELASKIN uses an indentation method with ruby-based measurement to quantify rigidity, firmness, and elasticity of skin with improved accuracy. The study will classify patients as diffuse cutaneous or limited cutaneous SSc based on skin fibrosis extent.

Tiaozhong-Yiqi Decoction RCT for Substance Withdrawal, 80 Patients

A randomized controlled clinical trial registered on ClinicalTrials.gov (NCT07543809) is evaluating Tiaozhong-Yiqi Decoction (TZYD) for treating substance withdrawal syndrome in 80 patients. The intervention group (n=40) receives 200mL TZYD twice daily for 3 months plus routine care; the control group (n=40) receives routine care only. Primary outcome measures withdrawal syndrome symptom improvement via standardized clinical scale; secondary outcomes include serum neurotransmitter levels (dopamine, norepinephrine, 5-hydroxytryptamine), inflammatory factors (IL-6, IL-1β, TNF-α), BDNF, and quality of life scores (QOL-DA V2.0). The study combines network pharmacology analysis with clinical validation to explore TZYD's potential regulatory mechanism on neuroendocrine and immune systems.

Digital Lifestyle Intervention for Migrants: RCT in Sweden

A randomized controlled trial (NCT07545239) will evaluate the feasibility, acceptability, and efficacy of a culturally and linguistically adapted 8-week digital lifestyle intervention targeting migrants with moderate psychological distress in Sweden. Participants (N=240) will be randomized to the digital intervention or a wait-list control receiving a general lifestyle module. Assessments will occur at baseline, post-treatment (8 weeks), 2-month follow-up, and 6-month follow-up.

Governor Braun Releases First Annual Direct-to-Employer Healthcare Review

The Indiana Department of Health Consumer Services and Healthcare Regulation Commission released its inaugural Direct-to-Employer Healthcare Arrangement Plan Review for calendar year 2025 at the direction of Governor Braun. The report found that all five participating health systems—Ascension St. Vincent, Community Health Network, Franciscan Health, Indiana University Health, and Parkview Health Network—met the statutory benchmark requiring employer-direct plans to remain at or below 260% of Medicare rates. The review provides employers new visibility into hospital pricing and highlights direct-to-employer contracting as a tool for managing healthcare costs.

14 Organizations Join USP Convention Including African Medicines Agency, Egyptian Drug Authority

USP added 14 organizations to its Convention as of Spring 2026, including the African Medicines Agency, Egyptian Drug Authority, Indonesian Food and Drug Authority, and Rwandan FDA, among others. The Convention now comprises over 450 member organizations from more than 50 countries representing science, manufacturing, regulatory, patient advocacy, government, and academia. Convention Members provide input and elect USP's Board of Trustees and Council of Experts, supporting USP's mission to protect and promote health by advancing quality across the lifecycle of medicines worldwide.

Wound Dressing Patent US12605285B2, HIDRAMED SOLUTIONS

The USPTO granted Patent US12605285B2 to HIDRAMED SOLUTIONS LTD on April 21, 2026, covering a wound dressing device that includes a retaining device for encompassing a portion of the body, a dressing, and a fastening element configured external to the retaining device. The patent application was filed on July 20, 2018, under application number 16637989, and contains 21 claims. The invention also relates to a method of applying the device and a combined dressing and fastening element.

US12605286B2 Infant Umbilical Cord Stump Protector

The USPTO granted Patent US12605286B2 to ASO LLC for an infant umbilical cord stump protector comprising a pad positionable proximal to the umbilical cord stump and a fluid-impermeable cover with adhesive, deformable, and peripheral regions that form a protective dome shape. The patent, filed on January 31, 2022 under Application No. 17588842, contains 51 claims and 18 CPC classifications in the A61F medical device category. Assignees and inventors seeking to commercialize similar neonatal care products should conduct freedom-to-operate analyses to avoid potential infringement of this issued patent.

Baxter Head Positioning Adapter Recall Type I

Baxter Corporation is recalling its Adapter For Head Positioning (Model 1739994) following identification that the device may become loose during patient positioning and unintentionally move when used with side rails of the upper back section H V U on Baxter operating tables. The recall affects three lot numbers—109943587, 109948552, and 109964961—and has been classified as Type I, the most serious recall category. Healthcare facilities using this device should contact Baxter for further information and follow any supplementary instructions issued by the firm.

Stryker Variax 2 Locking Screw - Non-Sterile, Lot AM5253

Health Canada has issued a Type II medical device recall for Stryker Gmbh's Variax 2 Locking Screw - Non-Sterile, Lot AM5253 (model/catalogue number 657328). Stryker confirmed that one lot was manufactured without the hexalobular feature required for mating with the associated screwdriver, creating a device incompatibility issue. Healthcare providers who have this product in stock should contact the manufacturer for additional information and next steps.

Observational Study Sensory Stimulation Brain Function

ClinicalTrials.gov registration NCT07544563 documents an observational behavioral and neurophysiological study examining the effects of controlled sensory stimulation (such as music) on brain function, with the study focusing on three conditions: Epilepsy, Anxiety, and Depression Anxiety Disorder. The study is registered as observational with no stated intervention, indicating it involves passive data collection rather than active treatment administration. This registration provides transparency into ongoing clinical research but creates no compliance obligations for any party.

Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

A randomized controlled trial (NCT07544667) has been registered on ClinicalTrials.gov to evaluate poly-L-lactic acid (Sculptra), an FDA-approved biostimulant, for the treatment of anterior wall pelvic organ prolapse (stage 2 cystocele) in women. The study will compare intravaginal PLLA injection versus placebo and will investigate safety and preliminary efficacy, including impact on sexual function. The trial plans to enroll women with stage 2 cystocele and follow them to assess whether regenerative biologics can shift prolapse management from surgical reconstruction to tissue regeneration.

PBM Study, Corniche Hospital, 2018-2025, Transfusion Reduction

ClinicalTrials.gov registry entry NCT07544017 describes an observational study conducted at Corniche Hospital assessing Patient Blood Management (PBM) implementation and blood product utilization among obstetric deliveries from 2018 to 2025. The primary objective is to estimate changes over time in mean blood product units transfused per delivery, with a hypothesis that increasing PBM maturity following comprehensive implementation in 2022 will correlate with significant reductions after adjusting for case-mix changes.

Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis (NCT07543900)

ClinicalTrials.gov registered study NCT07543900 titled 'Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis' evaluating virtual exercise-based interventions for patients with multiple sclerosis (MS). The study identifies conditions including Multiple Sclerosis, Exercise, Physical Therapy, Virtual Reality Exposure Therapy, and Rehabilitation Exercise. MS is described as a chronic neuroimmunological and degenerative disease and one of the leading causes of non-traumatic disability in young adults, with considerable healthcare burden. The trial is part of the ExeRVIEM II project examining high-intensity exercise programs with immersive VR.

Phase 2 JSKN003 Versus Trastuzumab for HER2+ Recurrent/Metastatic Breast Cancer

NIH registered Phase 2 randomized controlled trial NCT07545044 on April 22, 2026, comparing JSKN003 against trastuzumab combined with pertuzumab and docetaxel as first-line treatment for participants with HER2-positive recurrent or metastatic breast cancer who have not previously received systemic therapy for advanced disease. Participants who have undergone one prior endocrine treatment regimen remain eligible for enrollment. The open-label multicenter superiority trial is sponsored by an unnamed pharmaceutical entity and will assess both efficacy and safety endpoints.

Online Family Psychoeducation Trial for First-Episode Schizophrenia

NIH's ClinicalTrials.gov registry has posted a new study (NCT07545941) examining whether a mobile-based family psychoeducation program delivered via LINE application can reduce expressed emotion among family members and improve medication adherence in patients with first-episode schizophrenia. The single-arm trial is listed with an anticipated completion date of April 22, 2026. The registry entry identifies the condition as First-Episode Schizophrenia and specifies the intervention as a mobile-based family psychoeducation program.

36-Participant RCT Comparing Low-Dye and Calcaneal Taping for Plantar Fasciitis

A randomized controlled trial (NCT07544732) has been registered under the NIH ClinicalTrials.gov database, enrolling 36 participants with plantar fasciitis to compare Low-Dye taping versus Calcaneal taping over a two-week intervention period. The study will measure pain using the Visual Analogue Scale (VAS), functional ability via the Foot Function Index (FFI), ankle range of motion with a goniometer, and gait analysis, with statistical significance set at p < 0.05. This trial registration represents standard prospective clinical research documentation and does not impose any compliance obligations on regulated entities.

Adjuvant 5-Fluorouracil Following Thermal Ablation for HPV in Kenyan Women With HIV

This Phase 2 randomized, placebo-controlled clinical trial (NCT07545746) will evaluate self-administered 5% 5-fluorouracil (5FU) cream versus placebo to improve human papillomavirus (HPV) clearance after thermal ablation in women with HIV in Kenya. Participants will self-administer the cream intravaginally once every other week for 12 applications starting four weeks post-ablation, with clinic follow-up through 48 weeks. The trial's hypothesis is that 5FU will increase HPV clearance at 24 weeks and prove safe, well-tolerated, and acceptable in this population.

Health Web Te@m 1.0 Feasibility Study, Northern Sweden

A feasibility study for Health Web - Te@m 1.0, an interprofessional web-based group intervention supporting healthy ageing, has been registered on ClinicalTrials.gov under identifier NCT07545915. The study will evaluate the intervention's acceptability, implementation potential, adherence rates, and ability to detect outcomes among older adults in primary healthcare settings in northern Sweden. Conditions include Healthy Older Adults, with Health Web Te@m listed as the intervention type.

Ultrasound-Guided Low-Volume Brachial Plexus Block in Supraclavicular Region for Shoulder Reduction in Emergency Department

This NIH ClinicalTrials.gov registry entry documents NCT07544485, a retrospective, monocentric observational study analyzing routinely collected clinical data from an orthopedic emergency department between February 2018 and February 2024. The study evaluates the feasibility, safety, and clinical implementation of low-volume (approximately 5 ml local anesthetic) ultrasound-guided brachial plexus block in the supraclavicular region for adult patients with acute shoulder dislocation. Outcomes assessed include procedural success, block-related complications, and temporal trends reflecting adoption of the technique over time.

$43 Million to Make Local Water Infrastructure Projects Affordable Across New York State

The Environmental Facilities Corporation Board of Directors approved $43 million in low-cost financing and State and federal grants to help New York communities afford water and sewer infrastructure improvements statewide, including lead service line replacement in the City of Utica. Funding recipients span eight regions including the Finger Lakes, Long Island, Mohawk Valley, North Country, and Western New York, with projects addressing watermain replacement, PFAS removal, wastewater treatment plant upgrades, and emergency power facilities.

Hochul Announces $20M for Hospital Energy Efficiency and Electrification

Governor Hochul announced that more than $20 million is now available through NYSERDA's Empire Building Challenge: Hospitals (EBC: Hospitals) program for energy efficiency and electrification upgrades at hospitals in New York State. Individual awards of up to $5 million will be granted for scalable low-carbon solutions including building electrification, electrification readiness, and comprehensive energy efficiency projects achieving significant energy and carbon reductions. Hospitals in disadvantaged communities as defined by the New York Climate Justice Working Group will receive prioritization. Proposals are due September 15, 2026, by 3 p.m.; an informational webinar will be held April 22, 2026, at 10 a.m.

Takeda Vaccines Inc - EP4153222A1 - Zika Virus Antibody Detection

Takeda Vaccines, Inc. has obtained European Patent Application EP4153222A1 for a method of detecting Zika virus-specific antibodies. The application names inventors Perez-Guzman, Nascimento, Dean, and Braun and covers IPC classifications spanning immunological preparations, peptides, and nucleic acid detection methods. The patent is designated across 34 European states including Germany, France, the United Kingdom, Italy, and Spain.

EP4157335A2 Peptide Cocktail by Hubro Therapeutics AS

The European Patent Office published application EP4157335A2 filed by Hubro Therapeutics AS (Norway) for a peptide cocktail composition, with inventors Henrik Eriksen and Jon Amund Eriksen. The application was published April 15, 2026, under IPC classifications A61K 39/00 (immunological preparations), A61P 35/00 (antineoplastic agents), and C07K 14/00 (peptides), covering designated contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

EP4157861A1 - Anorexic Peptide Compositions and Uses by CSIC

The European Patent Office published application EP4157861A1 filed by Consejo Superior de Investigaciones Científicas (CSIC) for peptide compositions capable of inducing anorexic hormones, along with methods of use and pharmaceutical preparations. The application, covering IPC classifications including C07K 14/47, C07K 14/77, A61K 38/00, and A61P 3/04, names five inventors: Recio Sánchez, Santos Hernández, Miralles Buraglia, Hernández Ledesma, and Amigo Garrido. The application designates 33 European states including DE, FR, GB, IT, NL, ES, and SE.

Anti-HERV-W Envelope Protein Antibody for Psychotic Diseases, Geneuro SA

The European Patent Office published application EP4157871A1, filed by Geneuro SA and Fondamental, covering an anti-HERV-W envelope protein antibody for use in treating psychotic diseases. Inventors are Marion Leboyer and Hervé Perron. The application, classified under IPC C07K 16/28 (antibodies) and A61P 25/18 (CNS disorders/pscychotic diseases), designates all European Patent Convention member states. This is a routine patent application publication by the EPO Patent Bulletin.

GLP-2 Conjugate Pharmaceutical Composition for Metabolic Bone Diseases, Hanmi Pharm.

The European Patent Office published application EP4082561A1 for Hanmi Pharm. Co., Ltd. on April 15, 2026. The application covers a pharmaceutical composition comprising GLP-2 or a conjugate thereof for preventing or treating metabolic bone diseases, with inventors including CHOI Jae Hyuk, LEE Jin Bong, LEE Sang Hyun, LEE Sang Don, and KIM Min Young. The application spans 31 designated contracting states including major European economies.

Legend Biotech Single Domain Antibodies CAR-T BCMA

EPO published patent application EP4077398A1 covering single domain antibodies and chimeric antigen receptors targeting BCMA, assigned to Legend Biotech Ireland Limited and Legend Biotech USA Inc. The invention relates to cancer treatment methods using BCMA-targeted CAR-T cells and single domain antibodies. Six inventors are listed: Fan Xiaohu, Zhuang Qiuchuan, Zhao Yuncheng, Yang Lei, Fang Xu, and Xu Changmeng.

University of California MOG Peptide Glioblastoma Patent Application

The Regents of the University of California published European patent application EP4054596A1 on April 15, 2026, covering the use of MOG peptide for priming glioblastoma treatment. The application names six inventors and includes ten IPC classifications spanning peptide sequences, cancer therapeutics, and cellular immunotherapies across 31 designated contracting states.